Eisai China Completes Parenteral Facility in Suzhou

Eisai Co., a Japanese multinational pharma, completed construction of a new parenteral manufacturing plant in Suzhou. The facility is initially equipped with a production line for methycobal injection, a treatment for peripheral neuropathy and a major product for Eisai in China. The new facility has a capacity to manufacture 60 million ampoules per year. Over time, Eisai plans to expand the plant to become the company's main production facility for injection products intended for Asian and Latin American markets. More details.... Stock Symbol: (TO: 4523) Share this with colleagues: // //